Antibodies against dengue virus and related methods
Provided are antibodies or antigen binding portions thereof that specifically bind Dengue virus, various compositions of such antibodies or antigen binding portions thereof, and methods of their use. Provided are such antibodies, fragments of such antibodies retaining Dengue virus-binding ability, pharmaceutical compositions including such antibodies or antigen binding fragments thereof, and diagnostic compositions including such antibodies or antigen binding fragments thereof. Also provided are isolated nucleic acids encoding such antibodies, amino acid sequences of such antibodies, and host cells transformed therewith. Additionally, provided are prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the disclosure.
1. A synthetic antibody or antigen binding portion thereof comprising:
(a) a heavy chain variable region comprising
(i) a CDRH1 comprising SEQ ID NO:164
(ii) a CDRH2 comprising SEQ ID NO:199; and
(iii) a CDRH3 comprising SEQ ID NO:232; and
(b) a light chain variable region comprising
(i) a CDRL1 comprising SEQ ID NO:266;
(ii) a CDRL2 comprising SEQ ID NOs: 291; and
(iii) a CDRL3 comprising SEQ ID NO:308
or
(c) a heavy chain variable region comprising
(i) a CDRH1 comprising SEQ ID NO:163;
(ii) a CDRH2 comprising SEQ ID NO:198; and
(iii) a CDRH3 comprising SEQ ID NO:231; and
(d) a light chain variable region comprising
(i) a CDRL1 comprising SEQ ID NO:265;
(ii) a CDRL2 comprising SEQ ID NOs: 291; and
(iii) a CDRL3 comprising SEQ ID NO:307,
wherein the synthetic antibody or the antigen binding portion thereof is a Fab fragment, a F(ab′)2 fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge, an Fv fragment consisting of VL and VH domains of a single arm of an antibody, a single chain antibody Fv (scFv), or a diabody.
2. The synthetic antibody or the antigen binding portion thereof of claim 1 , comprising (a) and (b).
3. The synthetic antibody or the antigen binding portion thereof of claim 1 , comprising (c) and (d).
4. A pharmaceutical preparation comprising:
a pharmaceutically acceptable carrier; and
the synthetic antibody or the antigen binding portion thereof of claim 1 .
5. A diagnostic preparation comprising:
a pharmaceutically acceptable carrier; and
the synthetic antibody or the antigen binding portion thereof of claim 1 .
6. A method for treatment of dengue virus disease, comprising administering to a subject a therapeutically effective amount of the pharmaceutical preparation of claim 4 .
7. A method for the diagnosis of dengue virus disease, comprising:
administering to a subject an effective amount of the diagnostic preparation of claim 5 ; and,
detecting in the subject binding of the synthetic antibody or the antigen binding portion thereof as a determination of presence of the dengue virus disease.
8. A method of detecting presence of dengue virus in a biological sample, comprising:
contacting the biological sample with the diagnostic preparation of claim 5 , and
detecting in the biological sample an amount of binding of the synthetic antibody or the antigen binding portion thereof as a determination of presence of the dengue virus.
9. A method for treatment of dengue virus disease, comprising administering to a subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier, and a synthetic antibody or antigen binding portion thereof comprising one or both of
(1) a heavy chain variable region comprising
(i) a CDRH1 comprising SEQ ID NO:164;
(ii) a CDRH2 comprising SEQ ID NO:199; and
(iii) a CDRH3 comprising SEQ ID NO:232; and
a light chain variable region comprising
(i) a CDRL1 comprising SEQ ID NO:266;
(ii) a CDRL2 comprising SEQ ID NOs: 291; and
(iii) a CDRL3 comprising SEQ ID NO:308; or
(2) a heavy chain variable region comprising
(i) a CDRH1 comprising SEQ ID NO:163;
(ii) a CDRH2 comprising SEQ ID NO:198; and
(iii) a CDRH3 comprising SEQ ID NO:231; and
a light chain variable region comprising
(i) a CDRL1 comprising SEQ ID NO:265;
(ii) a CDRL2 comprising SEQ ID NOs: 291; and
(iii) a CDRL3 comprising SEQ ID NO:307.
10. A method for diagnosis of dengue virus disease comprising:
administering to a subject an effective amount of the of a composition comprising a synthetic antibody or antigen binding portion thereof comprising one or both of one or both of
(1) a heavy chain variable region comprising
(i) a CDRH1 comprising SEQ ID NO:164;
(ii) a CDRH2 comprising SEQ ID NO:199; and
(iii) a CDRH3 comprising SEQ ID NO:232; and
a light chain variable region comprising
(i) a CDRL1 comprising SEQ ID NO:266;
(ii) a CDRL2 comprising SEQ ID NOs: 291; and
(iii) a CDRL3 comprising SEQ ID NO:308; or
(2) a heavy chain variable region comprising
(i) a CDRH1 comprising SEQ ID NO:163;
(ii) a CDRH2 comprising SEQ ID NO:198; and
(iii) a CDRH3 comprising SEQ ID NO:231; and
a light chain variable region comprising
(i) a CDRL1 comprising SEQ ID NO:265;
(ii) a CDRL2 comprising SEQ ID NOs: 291; and
(iii) a CDRL3 comprising SEQ ID NO:307; and,
detecting in the subject binding of the synthetic antibody or the antigen binding portion thereof as a determination of presence of the dengue virus disease.
11. A method of detecting presence of dengue virus in a biological sample comprising:
contacting the biological sample with a composition comprising a synthetic antibody or antigen binding portion thereof comprising one or both of
(1) a heavy chain variable region comprising
(i) a CDRH1 comprising SEQ ID NO:164;
(ii) a CDRH2 comprising SEQ ID NO:199; and
(iii) a CDRH3 comprising SEQ ID NO:232; and
a light chain variable region comprising
(i) a CDRL1 comprising SEQ ID NO:266;
(ii) a CDRL2 comprising SEQ ID NOs: 291; and
(iii) a CDRL3 comprising SEQ ID NO:308; or
(2) a heavy chain variable region comprising
(i) a CDRH1 comprising SEQ ID NO:163;
(ii) a CDRH2 comprising SEQ ID NO:198; and
(iii) a CDRH3 comprising SEQ ID NO:231; and
a light chain variable region comprising
(i) a CDRL1 comprising SEQ ID NO:265;
(ii) a CDRL2 comprising SEQ ID NOs: 291; and
(iii) a CDRL3 comprising SEQ ID NO:307; and,
detecting in the biological sample an amount of binding of the synthetic antibody or the antigen binding portion thereof as a determination of presence of the dengue virus.